Free Trial

Tyra Biosciences (TYRA) 10K Form and Latest SEC Filings 2026

Tyra Biosciences logo
$33.93 -1.21 (-3.44%)
Closing price 04:00 PM Eastern
Extended Trading
$35.00 +1.07 (+3.15%)
As of 05:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Latest Tyra Biosciences SEC Filings & Recent Activity

Tyra Biosciences (NASDAQ:TYRA) has submitted 233+ documents to the U.S. Securities and Exchange Commission (SEC) since 2021. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in Tyra Biosciences's financial statements. The most recent filing was a Form SCHEDULE 13G/A submitted on April 24, 2026.

Form 4
Tyra Biosciences, Inc. Reports Ownership Change on Apr. 20, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
Tyra Biosciences Files Current Report on Apr. 17, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

Tyra Biosciences SEC Filing History

Browse Tyra Biosciences' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
04/24/2026 3:15 PM
Canaan XI L.P. (1712417) Filed by
Tyra Biosciences (1863127) Subject
Form SCHEDULE 13G/A
04/20/2026 3:30 PM
Dable Habib J (1690773) Reporting
Tyra Biosciences (1863127) Issuer
Form 3
Initial statement of beneficial ownership of securities  
04/20/2026 3:31 PM
Dable Habib J (1690773) Reporting
Tyra Biosciences (1863127) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/17/2026 7:08 AM
Tyra Biosciences (1863127) Filer
Form DEF 14A
04/17/2026 7:10 AM
Tyra Biosciences (1863127) Filer
Form DEFA14A
04/17/2026 7:11 AM
Tyra Biosciences (1863127) Filer
Form ARS
04/17/2026 7:02 AM
Tyra Biosciences (1863127) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/13/2026 3:44 PM
Bensen Daniel (1880946) Reporting
Tyra Biosciences (1863127) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/07/2026 12:33 PM
FMR LLC (315066) Filed by
Tyra Biosciences (1863127) Subject
Form SCHEDULE 13G
04/02/2026 3:38 PM
Rueb Yuliya (2125370) Reporting
Tyra Biosciences (1863127) Issuer
Form 3
Initial statement of beneficial ownership of securities  
03/27/2026 3:44 PM
KAPLAN GILLA (1247024) Reporting
Tyra Biosciences (1863127) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/25/2026 4:36 PM
KAPLAN GILLA (1247024) Reporting
Tyra Biosciences (1863127) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/12/2026 4:42 PM
Bensen Daniel (1880946) Reporting
Tyra Biosciences (1863127) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/06/2026 3:28 PM
RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by
Tyra Biosciences (1863127) Subject
Form SCHEDULE 13D/A
02/20/2026 7:14 AM
Farallon Capital Partners, L.P. (1175707) Filed by
Tyra Biosciences (1863127) Subject
Form SCHEDULE 13G
02/13/2026 3:30 PM
Harris Todd (1711463) Filed by
Tyra Biosciences (1863127) Subject
Form SCHEDULE 13G
02/13/2026 3:30 PM
Bensen Daniel (1880946) Reporting
Tyra Biosciences (1863127) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/20/2026 3:30 PM
Bensen Daniel (1880946) Reporting
Tyra Biosciences (1863127) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/12/2026 4:38 PM
Bensen Daniel (1880946) Reporting
Tyra Biosciences (1863127) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/19/2025 8:00 PM
MORE ROBERT J (1207792) Reporting
Tyra Biosciences (1863127) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/16/2025 3:30 PM
Bensen Daniel (1880946) Reporting
Tyra Biosciences (1863127) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/01/2025 5:16 PM
Ashar Bhavesh (1849740) Reporting
Tyra Biosciences (1863127) Issuer
Form 3
Initial statement of beneficial ownership of securities  
12/01/2025 5:17 PM
Ashar Bhavesh (1849740) Reporting
Tyra Biosciences (1863127) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/01/2025 7:00 AM
Tyra Biosciences (1863127) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/25/2025 4:00 PM
MORE ROBERT J (1207792) Reporting
Tyra Biosciences (1863127) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/21/2025 3:26 PM
Alta Partners NextGen Fund II, L.P. (1768658) Reporting
Tyra Biosciences (1863127) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/19/2025 6:30 PM
Bensen Daniel (1880946) Reporting
Tyra Biosciences (1863127) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/18/2025 4:04 PM
Bensen Daniel (1880946) Reporting
Tyra Biosciences (1863127) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/17/2025 6:03 PM
Bensen Daniel (1880946) Reporting
Tyra Biosciences (1863127) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/13/2025 4:40 PM
Bensen Daniel (1880946) Reporting
Tyra Biosciences (1863127) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/17/2025 4:57 PM
Fuhrman Alan (1303521) Reporting
Tyra Biosciences (1863127) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
08/21/2025 8:43 PM
Tyra Biosciences (1863127) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/14/2025 3:11 PM
Tyra Biosciences (1863127) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/14/2025 10:44 AM
JANUS HENDERSON GROUP PLC (1274173) Filed by
Tyra Biosciences (1863127) Subject
Form SCHEDULE 13G/A
08/07/2025 3:43 PM
Fuhrman Alan (1303521) Reporting
Tyra Biosciences (1863127) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/30/2025 7:07 AM
Tyra Biosciences (1863127) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/20/2025 4:42 PM
KAPLAN GILLA (1247024) Reporting
Tyra Biosciences (1863127) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/16/2025 7:06 PM
Kolchinsky Peter (1384859) Reporting
RA Capital Healthcare Fund LP (1315082) Reporting
RA CAPITAL MANAGEMENT, L.P. (1346824) Reporting
RA Capital Nexus Fund, L.P. (1780117) Reporting
Shah Rajeev M. (1619841) Reporting
Tyra Biosciences (1863127) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/16/2025 6:05 PM
KAPLAN GILLA (1247024) Reporting
Tyra Biosciences (1863127) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/13/2025 3:22 PM
KAPLAN GILLA (1247024) Reporting
Tyra Biosciences (1863127) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/11/2025 6:44 PM
Kolchinsky Peter (1384859) Reporting
RA Capital Healthcare Fund LP (1315082) Reporting
RA CAPITAL MANAGEMENT, L.P. (1346824) Reporting
RA Capital Nexus Fund, L.P. (1780117) Reporting
Shah Rajeev M. (1619841) Reporting
Tyra Biosciences (1863127) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/06/2025 3:50 PM
RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by
Tyra Biosciences (1863127) Subject
Form SCHEDULE 13D/A
05/18/2025 11:15 PM
Tyra Biosciences (1863127) Filer
Form EFFECT
05/14/2025 10:47 AM
JANUS HENDERSON GROUP PLC (1274173) Filed by
Tyra Biosciences (1863127) Subject
Form SCHEDULE 13G
05/12/2025 9:43 AM
FMR LLC (315066) Filed by
Tyra Biosciences (1863127) Subject
Form SCHEDULE 13G/A
05/08/2025 3:30 PM
Tyra Biosciences (1863127) Filer
Form S-3
Registration statement under Securities Act of 1933  
(Data available from 1/1/2016 forward)

Tyra Biosciences SEC Filings - Frequently Asked Questions

Tyra Biosciences (TYRA) has submitted 233+ filings to the SEC since 2021. You can browse the complete history or filter by form type using the tools above.

Tyra Biosciences's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results. Key financial data from these reports is available on Tyra Biosciences's financial statements page.

The most recent filing was a Form SCHEDULE 13G/A submitted on April 24, 2026. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:TYRA) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners